A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 465,400 shares of VTYX stock, worth $800,488. This represents 0.0% of its overall portfolio holdings.

Number of Shares
465,400
Previous 213,000 118.5%
Holding current value
$800,488
Previous $492,000 106.1%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.85 - $3.2 $466,940 - $807,680
252,400 Added 118.5%
465,400 $1.01 Million
Q2 2024

Aug 14, 2024

BUY
$2.31 - $5.59 $287,826 - $696,514
124,600 Added 140.95%
213,000 $492,000
Q1 2024

May 15, 2024

SELL
$1.9 - $10.13 $1.94 Million - $10.3 Million
-1,020,700 Reduced 92.03%
88,400 $486,000
Q4 2023

Feb 14, 2024

BUY
$2.08 - $31.18 $2.31 Million - $34.6 Million
1,109,100 New
1,109,100 $2.74 Million
Q2 2023

Aug 14, 2023

BUY
$28.53 - $39.55 $233,946 - $324,310
8,200 New
8,200 $268,000
Q4 2022

Feb 14, 2023

BUY
$24.16 - $36.38 $531,520 - $800,360
22,000 Added 275.0%
30,000 $983,000
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $101,120 - $309,600
8,000 New
8,000 $279,000

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $97.2M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.